Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy

OncoImmunology

Volumn 5, Issue 5, 2016, Pages

  Rittig, Susanne M ^a   Haentschel, Maik ^a   Weimer, Katrin J ^a   Heine, Annkristin ^b   Müller, Martin R ^a   Brugger, Wolfram ^c,f   Horger, Marius S ^a   Maksimovic, Olga ^a   Stenzl, Arnulf ^a   Hoerr, Ingmar ^d   Rammensee, Hans Georg ^a   Holderried, Tobias A ^b   Kanz, Lothar ^a   Pascolo, Steve ^e   Brossart, Peter ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CureVac GmbH   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Cancer; Dendritic cell; Human; Immunotherapy; Phase I II; Renal cell carcinoma; RNA; Survival; Trial; Vaccine

Indexed keywords

AXITINIB; BEVACIZUMAB; CAPECITABINE; EVEROLIMUS; GEMCITABINE; PAZOPANIB; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VINBLASTINE;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EVALUATION AND FOLLOW UP; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; KIDNEY CARCINOMA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MIDDLE AGED; NEPHRECTOMY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TUMOR GROWTH; VACCINATION;

EID: 84964690893     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1108511     Document Type: Article

References (33)

1. J.Banchereau, F.Briere, C.Caux, J.Davoust, S.Lebecque, Y.J.Liu, B.Pulendran, K.Palucka. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811; PMID:10837075; http://dx.doi.org/10.1146/annurev.immunol.18.1.767
2. S.Ishigami, S.Natsugoe, K.Tokuda, A.Nakajo, C.Xiangming, H.Iwashige, K.Aridome, S.Hokita, T.Aikou. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000; 159:103-8; PMID:10974412; http://dx.doi.org/10.1016/S0304-3835(00)00542-5
3. S.Ishigami, S.Natsugoe, M.Matsumoto, H.Okumura, H.Sakita, S.Nakashima, S.Takao, T.Aikou. Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 2003; 10:1237-40; PMID:12883687; http://dx.doi.org/10.3892/or.10.5.1237
4. M.Iwamoto, H.Shinohara, A.Miyamoto, M.Okuzawa, H.Mabuchi, T.Nohara, G.Gon, M.Toyoda, N.Tanigawa. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003; 104:92-7; PMID:12532424; http://dx.doi.org/10.1002/ijc.10915
5. N.Chaput, R.Conforti, S.Viaud, A.Spatz, L.Zitvogel. The Janus face of dendritic cells in cancer. Oncogene 2008; 27:5920-31; PMID:18836473; http://dx.doi.org/10.1038/onc.2008.270
6. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic Cell Death in Cancer Therapy. Ann Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
7. E.Noessner, D.Brech, A.N.Mendler, I.Masouris, R.Schlenker, P.U.Prinz. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012; 1:1451-3; PMID:23243626; http://dx.doi.org/10.4161/onci.21356
8. V.Sisirak, J.Faget, M.Gobert, N.Goutagny, N.Vey, I.Treilleux, S.Renaudineau, G.Poyet, S.I.Labidi-Galy, S.Goddard-Leon et al. Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression. Cancer Res 2012; 72:5188-97; PMID:22836755; http://dx.doi.org/10.1158/0008-5472.CAN-11-3468
9. E.Gilboa, J.Vieweg. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199:251-63; PMID:15233739; http://dx.doi.org/10.1111/j.0105-2896.2004.00139.x
10. A.Heiser, P.Dahm, D.R.Yancey, M.A.Maurice, D.Boczkowski, S.K.Nair, E.Gilboa, J.Vieweg. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000; 164:5508-14; PMID:10799919; http://dx.doi.org/10.4049/jimmunol.164.10.5508
11. Z.Su, J.Dannull, A.Heiser, D.Yancey, S.Pruitt, J.Madden, D.Coleman, D.Niedzwiecki, E.Gilboa, J.Vieweg. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63:2127-33; PMID:12727829
12. J.P.Carralot, J.Probst, I.Hoerr, B.Scheel, R.Teufel, G.Jung, H.G.Rammensee, S.Pascolo. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 2004; 61:2418-24; PMID:15378210; http://dx.doi.org/10.1007/s00018-004-4255-0
13. I.Hoerr, R.Obst, H.G.Rammensee, G.Jung. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000; 30:1-7; PMID:10602021; http://dx.doi.org/10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-
14. A.Heine, T.A.W.Holderried, P.Brossart. Immunotherapy in renal cell carcinoma. Immunotherapy 2009; 1:97-107; PMID:20635977; http://dx.doi.org/10.2217/1750743X.1.1.97
15. K.J.Kallen, R.Heidenreich, M.Schnee, B.Petsch, T.Schlake, A.Thess, P.Baumhof, B.Scheel, S.D.Koch, M.Fotin-Mleczek. A novel, disruptive vaccination technology: self-adjuvantedRNActive((R)) vaccines. Hum VaccinImmunother 2013; 9:2263-76; PMID:23921513; http://dx.doi.org/10.4161/hv.25181
16. C.Lorenz, M.Fotin-Mleczek, G.Roth, C.Becker, T.C.Dam, W.P.R.Verdurmen, R.Brock, J.Probst, T.Schlake. Protein expression from exogenous mRNA Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol 2011; 8:627-36; PMID:21654214; http://dx.doi.org/10.4161/rna.8.4.15394
17. E.Vacchelli, I.Vitale, A.Eggermont, W.H.Fridman, J.Fucikova, I.Cremer, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer et al. Trial Watch Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013 Oct 1; 2(10); PMID:24286020; http://dx.doi.org/10.4161/onci.25771
18. P.W.Kantoff, C.S.Higano, N.D.Shore, E.R.Berger, E.J.Small, D.F.Penson, C.H.Redfern, A.C.Ferrari, R.Dreicer, R.B.Sims et al. IMPACT Study Investigators. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
19. S.Walter, T.Weinschenk, A.Stenzl, R.Zdrojowy, A.Pluzanska, C.Szczylik, M.Staehler, W.Brugger, P.Y.Dietrich, R.Mendrzyk et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883
20. B.Escudier, T.Eisen, C.Porta, J.J.Patard, V.Khoo, F.Algaba, P.Mulders, V.Kataja; ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23:65-71; PMID:21436185; http://dx.doi.org/10.1093/annonc/mdr034
21. S.M.Rittig, M.Haentschel, K.J.Weimer, A.Heine, M.R.Muller, W.Brugger, M.S.Horger, O.Maksimovic, A.Stenzl, I.Hoerr et al. Intradermal Vaccinations With RNA Coding for TAA Generate CD8(+) and CD4(+) Immune Responses and Induce Clinical Benefit in Vaccinated Patients. MolTher 2011; 19:990-9; PMID:21189474; http://dx.doi.org/10.1038/mt.2010.289
22. R.J.Motzer, M.Mazumdar, J.Bacik, W.Berg, A.Amsterdam, J.Ferrara. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J ClinOncol 1999; 17:2530-40; PMID:10561319
23. D.Y.C.Heng, W.L.Xie, M.M.Regan, M.A.Warren, A.R.Golshayan, C.Sahi, B.J.Eigl, J.D.Ruether, T.Cheng, S.North et al. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. J ClinOncol 2009; 27:5794-9; PMID:19826129; http://dx.doi.org/10.1200/JCO.2008.21.4809
24. S.K.Pal, R.A.Nelson, N.Vogelzang. Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era. PLoS One 2013; 8 (5):e63341; PMID:23658823; http://dx.doi.org/10.1371/journal.pone.0063341
25. N.Kroeger, W.L.Xie, J.L.Lee, G.A.Bjarnason, J.J.Knox, M.J.MacKenzie, L.Wood, S.Srinivas, U.N.Vaishamayan, S.Y.Rha et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119:2999-3006; PMID:23696129; http://dx.doi.org/10.1002/cncr.28151
26. D.Y.C.Heng, W.L.Xie, M.M.Regan, L.C.Harshman, G.A.Bjarnason, U.N.Vaishampayan, M.Mackenzie, L.Wood, F.Donskov, M.H.Tan et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14:141-8; PMID:23312463; http://dx.doi.org/10.1016/S1470-2045(12)70559-4
27. M.R.Harrison, B.R.Hirsch, D.J.George, M.S.Walker, C.Chen, B.Korytowsky, E.Stepanski, A.P.Abernethy. Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. J OncolPract 2014; 10(2):e63-72; PMID:24281152; http://dx.doi.org/10.1200/JOP.2013.001180
28. E.Herrmann, N.Marschner, M.O.Grimm, C.H.Ohlmann, U.Hutzschenreuter, F.Overkamp, M.Groschek, K.Blumenstengel, G.Pühse, T.Steiner. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol 2011; 29(3):361-6; PMID:21461939; http://dx.doi.org/10.1007/s00345-011-0673-4
29. T.Wahlgren, U.Harmenberg, P.Sandström, S.Lundstam, J.Kowalski, M.Jakobsson, R.Sandin, B.Ljungberg. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Br J Cancer 2013; 108(7):1541-9; PMID:23531701; http://dx.doi.org/10.1038/bjc.2013.119
30. D.Shek, B.Tomlinson, M.Brown, A.Brunson, C.X.Pan, P.N.LaraJr. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. ClinGenitourin Cancer 2012; 10(2):93-98; PMID:22382008; http://dx.doi.org/10.1016/j.clgc.2012.01.007
31. R.J.Motzer, B.Escudier, D.F.McDermott, S.George, H.J.Hammers, S.Srinivas, S.S.Tykodi, J.A.Sosman, G.Procopio, E.R.Plimack et al. Nivolumabvs.Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; Nov 5; 373(19):1803-13; PMID:26406148; http://dx.doi.org/10.1056/NEJMoa1510665.
32. D.Wolf, A.Heine, P.Brossart. Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology 2014; 3:e27588; PMID:24800168; http://dx.doi.org/10.4161/onci.27588
33. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG, Pascolo S.Gene Ther. 2007 Aug; 14(15):1175-80